Trump’s plan offers tax and research benefits but marijuana rescheduling falls short of full legalization, leaving banking and legal gaps unresolved.
In a rare move with real policy teeth, former President Donald Trump is expected to reclassify marijuana under federal law—shifting it from Schedule I to Schedule III. For a cannabis industry still handcuffed by outdated laws and heavy tax burdens, that sounds like relief. But here’s the reality: This is not legalization. It’s a significant shift, yes, but not the sweeping reform many headlines suggest.
With cannabis still federally illegal, this rescheduling raises more questions than it answers. What changes, what doesn’t, and why are investors still jittery? Let’s break it down.
From Schedule I to Schedule III: The DEA’s Shifting Definitions
Cannabis has sat in Schedule I of the Controlled Substances Act since 1970. That’s the DEA’s most restrictive classification, reserved for drugs deemed to have “no currently accepted medical use” and a “high potential for abuse.” Heroin is Schedule I. So is LSD. Marijuana has long been in that mix—despite 38 states now legalizing some form of it for medical use.
Schedule III drugs, on the other hand, are recognized to have legitimate medical use and lower abuse potential. Think anabolic steroids and Tylenol with codeine. Moving cannabis to Schedule III acknowledges what researchers, patients, and even the Department of Health and Human Services (HHS) have said for years: cannabis is medicine. The move could finally align federal scheduling with reality.
Trump Steps In: Executive Action and Its Unknowns
Reports suggest Trump plans to initiate the rescheduling through executive order—a move that could speed up a process otherwise bogged down by red tape and DEA inertia. Unlike the Biden administration’s effort, which stalled amid bureaucratic delays and public comment periods, Trump’s approach may rely on direct rulemaking or fast-tracked administrative procedures.
Still, legal scholars note there’s no fast lane without friction. Whether through notice-and-comment rulemaking or an attempt at a direct final rule, any shift in scheduling is subject to legal review, potential lawsuits, and regulatory infighting. So far, no clear timeline has emerged. There’s only speculation, market reaction, and a wait-and-see posture from much of the industry .
Tax Relief: The Immediate Win for Cannabis Businesses
For cannabis operators, the biggest and most immediate upside lies in the tax code—specifically IRS Section 280E. Right now, businesses that “touch the plant” are barred from deducting ordinary business expenses due to cannabis’s Schedule I status. That means inflated tax bills, lower margins, and thin profits even for high-revenue operators.
Rescheduling to Schedule III would lift the 280E burden. That’s not just a line-item change—it’s a seismic shift in business viability. Cannabis companies would be able to deduct payroll, rent, and marketing expenses like any other legal business. The result? Improved cash flow, potential reinvestment, and a stronger foundation for long-term growth .
A Green Light for Research—At Last
Cannabis research in the U.S. has long been stifled by its Schedule I designation. Researchers have faced burdensome licensing requirements, restricted access to study-grade cannabis, and federal scrutiny that often bordered on sabotage.
With Schedule III status, the federal government finally acknowledges marijuana as having medical value. That’s not just symbolic—it lowers regulatory barriers for universities and clinical institutions to conduct peer-reviewed studies. Better data means better public health outcomes and could guide smarter cannabis policy down the road .
What Rescheduling Doesn’t Do: The Fine Print
Here’s where the hype train slows down.
Marijuana rescheduling does not legalize marijuana. It doesn’t grant access to traditional banking services. It doesn’t allow interstate commerce. And it definitely doesn’t open the door to institutional investors the way full federal legalization would.
Most importantly, rescheduling does nothing to address the people and communities still impacted by criminalization. Thousands remain incarcerated or carry cannabis-related criminal records in states that now permit adult use. Rescheduling, without more, offers them no relief.
Banks still treat cannabis companies like financial pariahs. Without Congressional action—like the repeatedly stalled SAFE Banking Act—operators remain locked out of basic services like loans and lines of credit. That leaves much of the industry dealing in cash, vulnerable to theft, and limited in scaling their businesses .
Investors Stay Cautious, Markets Stay Volatile
In the days surrounding early reports of Trump’s plan, cannabis stocks surged—then fell just as quickly. That volatility reflects an industry both eager for reform and wary of false starts. Without clarity on timelines, procedural pathways, or legal vulnerabilities, many institutional investors are holding back.
Until Congress takes definitive action—be it through banking reform or a federal legalization framework—the cannabis industry remains in legal limbo. That limbo discourages long-term capital and keeps valuations unpredictable .
What Comes Next: Reform or Regression?
Trump’s rescheduling move may be the most significant federal cannabis policy shift in decades. It acknowledges medical value, grants tax relief, and opens research doors. It’s not a comprehensive solution. Instead, it serves more as a new blueprint.
If meaningful change is going to happen, it must come through Congress. Bills proposing full federal legalization, banking reform, and expungement programs have all been introduced—some multiple times—but none have passed.
Whether Trump’s marijuana rescheduling plan creates momentum for legislative progress or becomes another dead-end gesture remains to be seen .
Also at stake is the fate of hemp-derived THC products, which currently live in a legal gray zone. With federal attention now pivoting toward cannabis reform, regulatory pressure may start to tighten around delta-8, THC-O, and other loophole cannabinoids. Any changes there could further reshape the U.S. cannabis economy—again, without full legalization .
Final Hit: What Marijuana Rescheduling Really Means
This moment is historic. Reclassifying marijuana to Schedule III dismantles one of the biggest lies in federal drug policy—that cannabis has no medical use. It also puts pressure on lawmakers and regulators to stop dragging their feet.
Still, let’s not confuse recognition with liberation. The industry remains constrained. Criminal justice reform is absent. The banking drought continues. And the patchwork of state laws, loopholes, and contradictions is as tangled as ever.
Rescheduling isn’t the endgame. It’s a middle move. But for now, it’s the move we’ve got.
***
Trap Culture is the ultimate destination for cannabis enthusiasts who want to experience the best of Arizona’s cannabis culture. Whether you are looking for the hottest cannabis-friendly events, the latest news on cannabis legalization, trends in the industry and exclusive, limited-edition products from the top brands in the market, Trap Culture has you covered. Visit our website to learn more about our events, our blog, and our store. Follow us on social media to stay updated on the latest news and promotions. Join the Trap Culture family and experience the most immersive and engaging social cannabis events in Arizona.
Follow us on social media
